Henry James International Management Inc. Has $343,000 Holdings in Cellectis SA (CLLS)
Henry James International Management Inc. lessened its holdings in shares of Cellectis SA (NASDAQ:CLLS) by 47.5% in the first quarter, HoldingsChannel.com reports. The fund owned 18,696 shares of the biotechnology company’s stock after selling 16,920 shares during the period. Henry James International Management Inc.’s holdings in Cellectis were worth $343,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in Cellectis by 24,158.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 48,517 shares of the biotechnology company’s stock worth $1,370,000 after acquiring an additional 48,317 shares during the period. Financial Gravity Companies Inc. acquired a new position in Cellectis during the 4th quarter worth $71,000. Point72 Asset Management L.P. boosted its position in Cellectis by 118.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 156,133 shares of the biotechnology company’s stock worth $4,406,000 after acquiring an additional 84,533 shares during the period. Macquarie Group Ltd. acquired a new position in Cellectis during the 3rd quarter worth $5,390,000. Finally, Morgan Stanley boosted its position in Cellectis by 25.2% during the 3rd quarter. Morgan Stanley now owns 481,450 shares of the biotechnology company’s stock worth $13,586,000 after acquiring an additional 96,847 shares during the period. Institutional investors own 27.61% of the company’s stock.
Several brokerages have recently weighed in on CLLS. Citigroup cut their price objective on Cellectis from $37.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, March 11th. BidaskClub lowered Cellectis from a “hold” rating to a “sell” rating in a report on Tuesday, March 26th. ValuEngine lowered Cellectis from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Barclays restated a “buy” rating and issued a $50.00 price objective on shares of Cellectis in a report on Wednesday, March 13th. Finally, William Blair began coverage on Cellectis in a report on Wednesday, March 13th. They issued an “outperform” rating for the company. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $32.00.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.14. The business had revenue of $3.08 million during the quarter, compared to analyst estimates of $7.46 million. Cellectis had a negative return on equity of 18.63% and a negative net margin of 362.48%. As a group, equities research analysts expect that Cellectis SA will post -2.78 EPS for the current year.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Further Reading: What is the S&P 500 Index?
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.